<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03905148</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-283/PD-0325901-AU-001</org_study_id>
    <nct_id>NCT03905148</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors</brief_title>
  <official_title>A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SpringWorks Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib)&#xD;
      combination in participants with tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">April 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Part A will consist of dose escalation and dose-finding components to establish the max tolerated dose and/or recommended Phase 2 dose Part B will investigate efficacy and further evaluate the PK, safety, and tolerability of the combination of PD-0325901 and BGB-283 (lifirafenib).</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>Approximately 2 years from date of the participants enrollment</time_frame>
    <description>Incidence and severity of AEs and SAEs and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence of DLT events and treatment-emergent AEs (TEAEs)</measure>
    <time_frame>Approximately 2 years from date of the participants enrollment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in participants with selected tumor types</measure>
    <time_frame>Approximately 2 years from date of the participants enrollment</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Solid Tumor, Adult</condition>
  <arm_group>
    <arm_group_label>Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination doses of, Mirdametinib at once a day and lifirafenib at once a day And Mirdametinib at twice a day and lifirafenib at once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-small cell lung cancer with confirmed K-RAS mutations, approximately 15 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endometrial cancer with confirmed K-RAS mutations, approximately 15 participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tumor type of interest based on preliminary anti-tumor clinical activities observed in Part A, approximately 15 participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lifirafenib</intervention_name>
    <description>RAF Dimer Inhibitor</description>
    <arm_group_label>Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens.</arm_group_label>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
    <other_name>BGB-283</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mirdametinib</intervention_name>
    <description>MEK Inhibitor</description>
    <arm_group_label>Part A: Dose Escalation/Dose finding Dose Level Cohorts ranging in dose levels and dose regimens.</arm_group_label>
    <arm_group_label>Part B: Group 1</arm_group_label>
    <arm_group_label>Part B: Group 2</arm_group_label>
    <arm_group_label>Part B: Group 3</arm_group_label>
    <other_name>PD-0325901</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Able to provide informed consent&#xD;
&#xD;
          2. Age 18 on day of signing informed consent form (ICF) or of the legal age of consent in&#xD;
             the jurisdiction in which the study is taking place&#xD;
&#xD;
          3. Advanced or metastatic, unresectable tumors (other than patients with tumors of the&#xD;
             brain or central nervous system) who have experienced disease progression&#xD;
&#xD;
               -  Part A: NSCLC, CRC, ovarian cancer, endometrial cancer, thyroid cancer, melanoma,&#xD;
                  pancreatic cancer, and other)&#xD;
&#xD;
               -  Part B: Group 1: NSCLC, Group 2: endometrial cancer, Group 3: Tumor types of&#xD;
                  interest based on preliminary anti-tumor activities observed in Part A&#xD;
&#xD;
          4. Must have archival tumor tissue or agree to tumor biopsy&#xD;
&#xD;
          5. Measurable disease per RECIST 1.1&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group performance status of less than or equal to 1&#xD;
&#xD;
          7. Life expectancy is greater than 12 weeks at the of signing ICF.&#xD;
&#xD;
          8. Adequate organ function and no transfusion within 14 days of first dose.&#xD;
&#xD;
          9. Females are of non-child bearing potential or willing to use contraception.&#xD;
&#xD;
         10. Males vasectomized or agree to use contraception.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Central Nervous System metastasis&#xD;
&#xD;
          2. Any retinal pathology considered to be a risk factor for central serous retinopathy&#xD;
&#xD;
          3. History of glaucoma&#xD;
&#xD;
          4. Active parathyroid disorder or history of malignancy associated hypercalcemia&#xD;
&#xD;
          5. Clinically significant cardiac disease within the past 6 months of signing ICF.&#xD;
&#xD;
          6. LVEF less than 50%&#xD;
&#xD;
          7. Abnormal QT interval at Screening&#xD;
&#xD;
          8. Severe uncontrolled systemic disease&#xD;
&#xD;
          9. HIV&#xD;
&#xD;
         10. Clinically significant active or known history of liver disease. (Hepatitis B and&#xD;
             Hepatitis C)&#xD;
&#xD;
         11. Hemorrhage or bleeding event at NCI-CTCAE v5.0 Grade 3 or higher within 28 days of&#xD;
             first dose.&#xD;
&#xD;
         12. history of or ongoing Von Willebrand disease and/or other past or present bleeding&#xD;
             disorders&#xD;
&#xD;
         13. Increased serum calcium&#xD;
&#xD;
         14. Inability to swallow oral medications&#xD;
&#xD;
         15. Ongoing radiation therapy or radio-cytotoxic therapy within prior 4 weeks. No&#xD;
             chemotherapy, immunotherapy, biologic therapy, hormonal, or molecular targeted therapy&#xD;
             within prior 2 weeks&#xD;
&#xD;
         16. Concomitant systemic or glucocorticoid therapy within 2 weeks&#xD;
&#xD;
         17. Major surgical procedure or significant traumatic injury within 4 weeks prior to first&#xD;
             dose or anticipates need for major surgery while on study&#xD;
&#xD;
         18. Concomitant medicines that are strong CYP3A inhibitors&#xD;
&#xD;
         19. History of toxicity from another RAF, MEK, ERK inhibitor requiring discontinuation of&#xD;
             treatment from these drugs&#xD;
&#xD;
         20. Underlying medical conditions in investigator's opinion to be unfavorable to be a part&#xD;
             of the study&#xD;
&#xD;
         21. Has been administered a live vaccine within 4 weeks (28 days) of initiation of study&#xD;
             treatment. NOTE: injectable seasonal vaccines for influenza and COVID-19 are generally&#xD;
             inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are&#xD;
             not allowed.&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katie Wood</last_name>
    <role>Study Director</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1 (877) 828-5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blacktown Cancer and Haematology Centre</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <zip>2148</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Prince of Wales Private Hospital - Specialist Medical Randwick</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B. Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors. J Clin Oncol. 2020 Jul 1;38(19):2140-2150. doi: 10.1200/JCO.19.02654. Epub 2020 Mar 17.</citation>
    <PMID>32182156</PMID>
  </results_reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2019</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

